← Search & browse all drugs
VARIOUS › ALL OTHER THERAPEUTIC PRODUCTS › ALL OTHER THERAPEUTIC PRODUCTS › Iron chelating agents
deferiprone
V03AC02
Forms & Strengths
- Oral tablets: 500 mg, 1000 mg
- Oral solution: 100 mg/mL
Adult Dosing
- Initial dose: 25 mg/kg orally three times daily (total daily dose: 75 mg/kg)
- Maximum dose: 33 mg/kg three times daily (total daily dose: 99 mg/kg)
- Dose adjustments based on serum ferritin levels and clinical response
Pediatric Dosing
- Indicated for pediatric patients aged 8 years and older
- Initial dose: 25 mg/kg orally three times daily (total daily dose: 75 mg/kg)
- Maximum dose: 33 mg/kg three times daily (total daily dose: 99 mg/kg)
Indications
- Treatment of transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate
Mechanism of Action
- Iron chelating agent that binds to ferric (Fe3+) iron in a 3:1 molar ratio
- Forms a stable, water-soluble complex that is eliminated primarily via renal excretion
- Promotes removal of excess myocardial and hepatic iron stores
Contraindications
- Hypersensitivity to deferiprone or any component of the formulation
- History of severe or recurrent neutropenia
Adverse Reactions
- Agranulocytosis and severe neutropenia
- Chromaturia (red-brown urine)
- Nausea, vomiting, and abdominal pain
- Arthralgia and joint swelling
- Elevated serum alanine aminotransferase (ALT)
- Thrombocytopenia
Drug Interactions
- Concurrent use with other drugs known to cause neutropenia or agranulocytosis requires caution
- Do not co-administer with aluminum-containing antacids due to chelation of aluminum
- Potential for chelation of multivalent cations (iron, aluminum, zinc); separate administration if necessary
Curated Content: Needs Vetting Before Put to Clinical Use